1. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Issue 3 (March 2022) Authors: Kremsner, Peter G; Ahuad Guerrero, Rodolfo Andrés; Arana-Arri, Eunate; Aroca Martinez, Gustavo Jose; Bonten, Marc; Chandler, Reynaldo; Corral, Gonzalo; De Block, Eddie Jan Louis; Ecker, Lucie; Gabor, Julian Justin; Garcia Lopez, Carlos Alberto; Gonzales, Lucy; Granados González, María Angélica; G... Journal: Lancet infectious diseases Issue: Volume 22:Issue 3(2022) Page Start: 329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Multi-analyte profiling of inflammatory mediators in COPD sputum – The effects of processing. Issue 2 (February 2015) Authors: Pedersen, Frauke; Holz, Olaf; Lauer, Gereon; Quintini, Gianluca; Kiwull-Schöne, Heidrun; Kirsten, Anne-Marie; Magnussen, Helgo; Rabe, Klaus F.; Goldmann, Torsten; Watz, Henrik Journal: Cytokine Issue: Volume 71:Issue 2(2015) Page Start: 401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study. (August 2022) Authors: Sáez-Llorens, Xavier; Lanata, Claudio; Aranguren, Elaine; Celis, Carlos R.; Cornejo, Rubelio; DeAntonio, Rodrigo; Ecker, Lucie; Garrido, Diegi; Gil, Ana I.; Gonzales, Marina; Hess-Holtz, Morgan; Leroux-Roels, Geert; Junker, Helga; Kays, Sarah-Katharina; Koch, Sven D.; Lazzaro, Sandra; Mann, Phili... Journal: Vaccine Issue: Volume 11(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗